ChromaDex's Niagen receives regulatory authorizations in Europe & Australia
ChromaDex announced regulatory authorizations to sell its patented nicotinamide riboside chloride - NR, or Niagen - to consumers in both the European Union and in Australia. ChromaDex received its listing number for Tru Niagen on the Australian Registry of Therapeutic Goods on January 8. The company also received authorization to sell its patented nicotinamide riboside chloride as a novel food in the European Union on January 10. As the regulatory applicants and innovators, ChromaDex benefits from market exclusivity in Australia until December 2021 and market exclusivity in the EU until February 2025. ChromaDex also secured regulatory approval on its patent-protected ingredient in Canada.